Leonardi M, Cirillo L, Toni F, Dall'olio M, Princiotta C, Stafa A, Simonetti L, Agati R
Neuroradiology Department, University of Bologna, Bologna, Italy.
Interv Neuroradiol. 2011 Sep;17(3):306-15. doi: 10.1177/159101991101700305. Epub 2011 Oct 17.
The Silk stent (Balt, Montmorency, France) is a retractable device designed to achieve curative reconstruction of the parent artery associated with an intracranial aneurysm. We present our initial experience with the Silk flow-diverting stent in the management and follow-up of 25 patients presenting with intracranial aneurysms.Twenty-five patients (age range, 34-81 years; 24 female) were treated with the Silk flow-diverting device. Aneurysms ranged in size from small (5), large (10) and giant (10) and included wide-necked aneurysms, multiple, nonsaccular, and recurrent intracranial aneurysms. Nine aneurysms were treated for headache, 14 for mass effect. None presented with haemorrhage. All patients were pretreated with dual antiplatelet medications for at least 72 hours before surgery and continued taking both agents for at least three months after treatment. A total of 25 Silk stents were used. Control MR angiography and/or CT angiography was typically performed prior to discharge and at one, three, six and 12 months post treatment. A follow-up digital subtraction angiogram was performed between six and 19 months post treatment.Complete angiographic occlusion or subtotal occlusion was achieved in 15 patients in a time frame from three days to 12 months. Three deaths and one major complication were encountered during the study period. Two patients, all with cavernous giant aneurysms, experienced transient exacerbations of preexisting cranial neuropathies and headache after the Silk treatment. Both were treated with corticosteroids, and symptoms resolved completely within a month.In our experience the Silk stent has proven to be a valuable tool in the endovascular treatment of intracranial giant partially thrombosed aneurysms and aneurysms of the internal carotid artery cavernous segment presenting with mass effect. The time of complete occlusion of the aneurysms and the risk of the bleeding is currently not predictable.
Silk支架(法国巴尔的摩市蒙特莫伦西的Balt公司生产)是一种可回缩装置,旨在对与颅内动脉瘤相关的载瘤动脉进行根治性重建。我们介绍了使用Silk血流导向支架治疗和随访25例颅内动脉瘤患者的初步经验。
25例患者(年龄范围34 - 81岁;24例女性)接受了Silk血流导向装置治疗。动脉瘤大小从小型(5例)、大型(10例)到巨大型(10例)不等,包括宽颈动脉瘤、多发、非囊状和复发性颅内动脉瘤。9例动脉瘤因头痛接受治疗,14例因占位效应接受治疗。无一例出现出血。所有患者在手术前至少72小时接受双重抗血小板药物预处理,并在治疗后至少持续服用这两种药物三个月。共使用了25枚Silk支架。通常在出院前以及治疗后1个月、3个月、6个月和12个月进行对照磁共振血管造影和/或CT血管造影。在治疗后6至19个月进行随访数字减影血管造影。
15例患者在3天至12个月的时间内实现了完全血管造影闭塞或次全闭塞。研究期间发生3例死亡和1例严重并发症。2例均为海绵窦巨大动脉瘤的患者在Silk治疗后出现原有颅神经病变和头痛的短暂加重。两者均接受了皮质类固醇治疗,症状在1个月内完全缓解。
根据我们的经验,Silk支架已被证明是颅内巨大部分血栓形成动脉瘤和出现占位效应的颈内动脉海绵窦段动脉瘤血管内治疗的一种有价值的工具。目前,动脉瘤完全闭塞的时间和出血风险尚不可预测。